University of California Riverside scientists report that compounds beyond THC may significantly influence how the body responds to cannabis, opening research avenues into non-intoxicating cannabinoids with distinct physiological effects.
The team profiled metabolic products from lesser-studied cannabinoids present in modern high-potency strains and hemp derivatives, finding interactions with immune and pain signaling pathways independent of classic CB1 receptor intoxication mechanisms.
Legalization across many U.S. states increased consumer exposure to diverse formulations including edibles and concentrates with variable cannabinoid ratios not captured by THC percentage labeling alone. Regulators struggle to keep testing standards aligned with emerging product chemistries.
Pharmaceutical interest includes isolating specific compounds for targeted therapies without psychoactive side effects that limit prior medical marijuana trials. UC Riverside collaborators are expanding mass spectrometry libraries to identify rare cannabinoids in botanical samples.
Public health officials caution that broader compound effects do not imply safety of unregulated products lacking quality control. Peer reviewers requested in vivo confirmation of key pathway findings observed primarily in cell culture models initially.
Publication coincided with ongoing federal scheduling reviews affecting research supply access for universities.
State cannabis regulators said expanded cannabinoid profiling could improve product labeling as consumers encounter formulations with varying ratios beyond THC potency alone.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://scitechdaily.com/